Invention Grant
- Patent Title: Antibodies specific to CD40 and uses thereof
-
Application No.: US16724409Application Date: 2019-12-23
-
Publication No.: US10654939B1Publication Date: 2020-05-19
- Inventor: Wenqi Hu , Jiangmei Li , Feng Li
- Applicant: Beijing Mabworks Biotech Co., Ltd. , Beijing Mabridge Biopharmaceutical Co., Ltd
- Applicant Address: CN Beijing CN Beijing
- Assignee: BEIJING MABWORKS BIOTECH CO., LTD.,BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
- Current Assignee: BEIJING MABWORKS BIOTECH CO., LTD.,BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
- Current Assignee Address: CN Beijing CN Beijing
- Agency: Duane Morris LLP
- Agent Thomas J. Kowalski; Deborah L. Lu
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/28 ; C07K16/46 ; A61K39/395 ; A61K31/282 ; A61K31/704 ; A61P35/00 ; A61K38/20 ; A61K38/19

Abstract:
An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
Information query